(Q31521336)

2 July 2017

1 reference

title

Recent progress in antiviral chemotherapy for respiratory syncytial virus infections (English)

1 reference

2 July 2017

0 references

S Shigeta

1

1 reference

PubMed ID

11060673

2 July 2017

language of work or name

English

0 references

publication date

1 February 2000

1 reference

Expert Opinion on Investigational Drugs

2 July 2017

1 reference

2 July 2017

9

1 reference

2 July 2017

2

1 reference

2 July 2017

221-235

1 reference

National surveillance for respiratory syncytial virus, United States, 1985-1990.

2 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Report of a Workshop on Respiratory Syncytial Virus and Parainfluenza Viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Mouse model of respiratory syncytial virus infection to evaluate antiviral activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

An outbreak of respiratory syncytial virus in a bone marrow transplant center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Respiratory Syncytial Virus Infections in Pediatric Liver Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Risk factors for mechanical ventilation in respiratory syncytial virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

What link between early respiratory viral infections and atopic asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Respiratory syncytial virus and influenza A infections in the hospitalized elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

An epidemic of respiratory syncytial virus in elderly people: clinical and serological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Respiratory syncytial virus infection in immunocompromised adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Respiratory syncytial virus infection among intubated adults in a university medical intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

The use of eye-nose goggles to control nosocomial respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Prevention of nosocomial respiratory syncytial virus infections through compliance with glove and gown isolation precautions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Prospective controlled study of four infection-control procedures to prevent nosocomial infection with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Biochemistry and clinical applications of ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Respiratory syncytial virus (RSV) disease and prospects for its control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Neonatal respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high risk children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and 6'-(R)-6'-C-methylneplanocin A against several ortho- and paramyxoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Targeting RNA for degradation with a (2'-5')oligoadenylate-antisense chimera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

DNA and RNA virus species are inhibited by xanthates, a class of antiviral compounds with unique properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Antiviral effects of xanthate D609 on the human respiratory syncytial virus growth cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Synthesis, characterization, and biological activity of a new potent class of anti-HIV agents, the peroxoniobium-substituted heteropolytungstates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Activity of the Keggin polyoxotungstate PM-19 against herpes simplex virus type 2 infection in immunosuppressed mice: role of peritoneal macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

SP-303 small-particle aerosol treatment of influenza A virus infection in mice and respiratory syncytial virus infection in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

The antiviral activity of SP-303, a natural polyphenolic polymer, against respiratory syncytial and parainfluenza type 3 viruses in cotton rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

Novel anti-respiratory syncytial(RS) viral compounds: benzodithiin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.221

21 January 2018

Identifiers

DOI

10.1517/13543784.9.2.221

1 reference

2 July 2017

1 reference

PubMed ID

11060673